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KCNQ1OT1Beckwith–Wiedemann syndrome has a wide spectrum of complications such as embryonal tumors, namely ad-
renocortical tumor. Tumor predisposition is one of the most challenging manifestations of this syndrome. A 45-
day old female with a family history of adrenocortical tumor presented with adrenocortical tumor. The case
raised suspicion of a hereditary Beckwith–Wiedemann syndrome, therefore molecular analysis was undertaken.
The results revealed partial KCNQ1OT1 hypomethylation in the infant's blood DNA which was associated with a
complete loss of methylation in the infant's adrenocortical tumor tissue. It is unique for familial Beckwith–
Wiedemann syndrome caused by KCNQ1OT1 partial hypomethylation to manifest solely through adrenocortical
tumor. Incomplete penetrance and speciﬁc tissue mosaicism could provide explanations to this novel hereditary
Beckwith–Wiedemann syndrome presentation.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
BWS (OMIM # 130650) consists of a constellation of manifestations
includingmacrosomia, macroglossia, abdominal wall defects and tumor
predisposition (Thorburn et al., 1970; Engstrom et al., 1988). It is caused
by various epigenetic and/or genetic alterations that deregulate the
imprinted genes on chromosome 11p15.5 (Weksberg et al., 2003).
Besides surgical management of macroglossia and abdominal wall de-
fects, genetic predisposition for cancer seems to be themost challenging
issue in BWS patient's management. Once the molecular diagnosis is
established, hereditary transmission already reported in 15% (Bliek
et al., 2001) of BWS cases could provide a clue in tumor screening and
follow-up.
We report a case of partial KCNQ1OT1 hypomethylation causing
hereditary BWS. The latter is presented solely with a benign adrenocor-
tical tumor (ACT) in a 45-day old baby femalewith family history of ACT
in her paternal aunt.
2. Clinical report
A 45-day old female of healthy parents was referred to the Pediatric
Department for investigation of rapid weight gain. She was born at216 73 102 595.
-Brahim).
. This is an open access article under39 weeks of gestation by cesarean section in response to a fetal distress.
The birth weight was 4 kg (97 percentile) and clinical ﬁndings at birth
were normal. In a physical examination, the subject weighed 5.6 kg
(N97th percentile), and her blood pressure was 95/46 mm Hg. The
infant had cushingoid features: a “buffalo hump” and a “moon face”
with hypertrichosis. A lump was felt in the left upper quadrant of the
abdomen. We found neither abdominal wall defect nor organomegaly.
The genital organs were normal.
In the family history, her paternal aunt (65 years) was diagnosed
with benign left adrenal tumor, which was surgically removed at the
age of 60. Laboratory ﬁndings showed normal 24-h glucose proﬁle.
Endocrine investigations revealed a high level of both urinary free corti-
sol excretion and serumcortisol in circadian rhythm (serumcortisol at 8
a.m.was 1640 μg/l). It was also noted that serum testosterone level was
high,while theACTH levelwaswithinnormal range. The level of VMA in
the urinary excretion of 24 h was also normal.
CT-scan detected a left isolated adrenal necrotic tissue mass of
6 cm × 4 cm. A surgical resection was undertaken. The histopatho-
logical examination showed a typical benign ACT. Immediate post-
operative outcomes were satisfactory and the cushingoid appear-
ance was gradually improving. After 9 months of follow-up, the in-
fant weighed 9 kg (75th percentile) and serum cortisol at 8 a.m.
was down to 39 μg/l. The thoracic and abdominal CT scan control
was normal. This list of ﬁndings raised suspicion of a hereditary
BWS, hence molecular analyses were undertaken.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
IC1 and IC2 methylation index according to MS-MLPA analysis.
Methylation index
IC1 IC2




Baby tumor DNA 0.56 0.05
Baby skin DNA 0.56 0.54
Footnotes:
Methylation status is determined according to MS-MLPA recommendations.
Methylation index (MI) below 0.5 indicates a loss of methylation, MI between 0.6 and 0.5
indicates a normal methylation pattern and MI above 0.6 indicates a hypermethylation.
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In order to investigate BWS epigenetic alterations, we opted for BWS
speciﬁcally designed MS-MLPA (methylation-sensitive multiplex
ligation probe ampliﬁcation) kit (ME030 BWS/RSS). MS-MLPA reaction
is a semi-quantitative method for methylation proﬁling, in which copy
number detection is combined with the use of methylation-sensitive
restriction enzyme.
DNA was extracted from blood samples from the baby, her parents
and paternal aunt using FlixiGene DNA kit. DNA was also extracted
from the tumor and skin tissues of the baby using the phenol/
chloroform DNA extraction protocol. All 6 DNA samples were analyzed
using the ME030 BWS/RSS MS-MLPA kit.
While MS-MLPA analysis of the ACT tumor tissue revealed a com-
plete loss of methylation at KCNQ1OT1 gene, the baby's blood DNA
showed a partial loss of methylation at the same imprinting center,
and the baby's skin tissue showed a normal methylation proﬁle
(Fig. 1, Table. 1). The aunt's blood DNAMS-MLPA analysis unexpectedly
showed a normal methylation proﬁle (Table. 1). As such, tumor DNA
was not available. Blood DNA analysis from both parents was strictly
normal.
4. Discussion
BWS has a wide phenotypic spectrum including pre and postnatal
overgrowth, macroglossia and anterior abdominal wall defects
(Thorburn et al., 1970). Additional and variable complications may
occur such as organomegaly, hypoglycemia, hemihypertrophy, genito-
urinary abnormalities and rarely embryonal tumors like Wilms tumors
and adrenocortical tumor which are reported in approximately 5% of
cases (Reik and Maher, 1997; Ribeiro et al., 2000). Given the numerous
manifestations of BWS, two consensuses about BWS diagnosis criteria
were established. BWS diagnosis is determined either according to the
criteria of Elliott et al. (1994) or according to the criteria of DeBaun
and Tucker (1998).
Although it has well been described as part of BWS clinical manifes-
tations, childhood ACT is considered neither by Elliot nor by DeBaunFig. 1. Pedigree of the three generation family showing IC1 and IC2 methylation pattern
: IC2; : IC1; : complete methylation; : partial methylation; : patients with
ACT; P: paternal allele; M: maternal allele. Generation order: I, II and III.criteria. Our patient showed only one BWS criterion, i.e. pre and postna-
tal overgrowth and hence does not comply with either the Elliot or the
DeBaun criteria. According to Bliek et al. (2001) the diagnosis of BWS in
our patient would be classiﬁed as doubtful.
The genetics of BWS is complex; indeed imprinting genes implicated
in BWS belong to 2 imprinting domains IC1 and IC2 at 11p15. The IGF2
gene and the closed linked H19 gene are located in the centromeric
imprinting center IC1, whereas the growth regulator gene CDKN1C, a
subunit of KCNQ1 gene, and its overlapping transcript KCNQ1OT1 are lo-
cated in the telomeric imprinting center IC2 (Weksberg et al., 2003).
Loss of methylation at KCNQ1OT1 occurs in 50% of patients (Weksberg
and Shuman, 2000) while gain-of-methylation defects occurring at IC1
concerns only 5% of BWS patients. Epigenetic alterations that involve
both IC1 and IC2 are reported in 20% of cases and indicate paternal uni-
parental disomy (UPD) (Cooper et al., 2005; Choufani et al., 2010).
CDKN1C point mutations concern a small fraction of BWS patients
(Lam et al., 1999). Although most patients have a normal karyotype, a
number of BWS patients display chromosomal abnormalities including
translocations, inversions, partial 11p15 trisomy, IC2 microdeletions
and IC1 microduplications (Pettenati et al., 1986).
Most BWS cases are sporadic but family inheritance has been report-
ed in 15% of cases (Bliek et al., 2001). The imprinting genomic defects
are reported in patients with hereditary BWS at a higher prevalence of
CDKN1C point mutations, IC2 microdeletions and IC1microduplications
(Niemitz et al., 2004). Most hereditary KCNQ1OT1methylation defects
are either due to IC2 microdeletion or associated with IC1 hypermethy-
lation, hence to UPD (Bliek et al., 2001).
Nonetheless KCNQ1OT1 hypomethylation associated with a normal
IC1 methylation status has already been reported in familial BWS
(Bliek et al., 2001). Jet Bliek reported 31 BWSpatients, including 4 famil-
ial cases, all displaying normal IC1 methylation and hypomethylation of
KCNQ1OT1. Interestingly, none of those patients had developed a tumor.
Although ACT is known to correlate to H19 hypermethylation,
hence to IC1 hypermethylation, few cases of sporadic ACT displaying
KCNQ1OT1hypomethylationwere reported. PartialKCNQ1OT1hypome-
thylation reported in our patient's blood DNAhas already been reported
in 29 out of 40 non-UPD patients (Bliek et al., 2001).
The infant's paternal aunt with surgically managed ACT remains the
only evidence of BWS hereditary transmission in our patient. Lindor
et al. already suggested that, besides several other clinical criteria,
other family members affected with ACT may raise suspicion of BWS
(Lindor et al., 2008).
The present study reports a unique familial BWS caused by partial
KCNQ1OT1 hypomethylation, solely expressed through ACT. Our patient
is likely to have inherited the imprinting defect from her father. As pre-
viously described, a milder phenotype is assigned to paternal transmit-
tance of BWS. Incomplete penetrance could provide an explanation to
under-diagnosis of familial cases. Although the father (II.1, Fig. 1) and
the aunt (I.3, Fig. 1) did not show KCNQ1OT1 hypomethylation in their
blood DNAs, a speciﬁc familial tissue mosaicism could underlie this
special constellation.
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Tumor predisposition is a challenging manifestation of BWS. It is
unique for familial BWS caused by KCNQ1OT1 partial hypomethylation
to express solely through adulthood and childhood ACT. Incomplete
penetrance and speciﬁc familial tissue mosaicism could provide
explanations to this mild hereditary BWS presentation.
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